Cargando…

Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy

Epidermal growth factor receptor monoclonal antibody was approved for treatment of metastatic colorectal cancer patients carrying KRAS wild type DNA. However, recent studies showed that patients with KRAS G13D mutation may benefit from EGFR antibody therapy. In this study we tried to explore whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shaorong, Xiao, Xia, Lu, Jianwei, Qian, Xiaoping, Liu, Baorui, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706612/
https://www.ncbi.nlm.nih.gov/pubmed/23874486
http://dx.doi.org/10.1371/journal.pone.0068022
_version_ 1782276382922899456
author Yu, Shaorong
Xiao, Xia
Lu, Jianwei
Qian, Xiaoping
Liu, Baorui
Feng, Jifeng
author_facet Yu, Shaorong
Xiao, Xia
Lu, Jianwei
Qian, Xiaoping
Liu, Baorui
Feng, Jifeng
author_sort Yu, Shaorong
collection PubMed
description Epidermal growth factor receptor monoclonal antibody was approved for treatment of metastatic colorectal cancer patients carrying KRAS wild type DNA. However, recent studies showed that patients with KRAS G13D mutation may benefit from EGFR antibody therapy. In this study we tried to explore whether the abundance of KRAS mutation could affect the efficacy of EGFR antibody therapy. We firstly established a PNA-PCR method which could calculate the percentage of KRAS mutation in total DNA and proved its ability on 47 colorectal cancer samples bearing KRAS mutations. Then we analyzed the correlation between the abundance of KRAS mutations and efficacy of EGFR antibody therapy in another 35 metastatic colorectal cancer patients. We proved that PNA-PCR assay could calculate the abundance of KRAS mutation and the percentage of mutant DNA in tumor cells varied a lot (10.8%∼98.3%) on the 47 colorectal cancer patients. The efficacy of EGFR antibody correlated with the abundance of KRAS mutations: in the KRAS mutation less than 30% group, the disease control rate was 44.4% (4/9); the disease control rate of 30∼80% group was 5.6% (1/18) and the >80% group was 12.5% (1/8) (P = 0.038). In summary, our study showed that PNA-PCR method could easily detect the percentage of KRAS mutation in tumor cells and colorectal cancer patients with low abundance of KRAS mutation might benefit from EGFR antibody therapy.
format Online
Article
Text
id pubmed-3706612
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37066122013-07-19 Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy Yu, Shaorong Xiao, Xia Lu, Jianwei Qian, Xiaoping Liu, Baorui Feng, Jifeng PLoS One Research Article Epidermal growth factor receptor monoclonal antibody was approved for treatment of metastatic colorectal cancer patients carrying KRAS wild type DNA. However, recent studies showed that patients with KRAS G13D mutation may benefit from EGFR antibody therapy. In this study we tried to explore whether the abundance of KRAS mutation could affect the efficacy of EGFR antibody therapy. We firstly established a PNA-PCR method which could calculate the percentage of KRAS mutation in total DNA and proved its ability on 47 colorectal cancer samples bearing KRAS mutations. Then we analyzed the correlation between the abundance of KRAS mutations and efficacy of EGFR antibody therapy in another 35 metastatic colorectal cancer patients. We proved that PNA-PCR assay could calculate the abundance of KRAS mutation and the percentage of mutant DNA in tumor cells varied a lot (10.8%∼98.3%) on the 47 colorectal cancer patients. The efficacy of EGFR antibody correlated with the abundance of KRAS mutations: in the KRAS mutation less than 30% group, the disease control rate was 44.4% (4/9); the disease control rate of 30∼80% group was 5.6% (1/18) and the >80% group was 12.5% (1/8) (P = 0.038). In summary, our study showed that PNA-PCR method could easily detect the percentage of KRAS mutation in tumor cells and colorectal cancer patients with low abundance of KRAS mutation might benefit from EGFR antibody therapy. Public Library of Science 2013-07-09 /pmc/articles/PMC3706612/ /pubmed/23874486 http://dx.doi.org/10.1371/journal.pone.0068022 Text en © 2013 Yu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Yu, Shaorong
Xiao, Xia
Lu, Jianwei
Qian, Xiaoping
Liu, Baorui
Feng, Jifeng
Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title_full Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title_fullStr Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title_full_unstemmed Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title_short Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
title_sort colorectal cancer patients with low abundance of kras mutation may benefit from egfr antibody therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706612/
https://www.ncbi.nlm.nih.gov/pubmed/23874486
http://dx.doi.org/10.1371/journal.pone.0068022
work_keys_str_mv AT yushaorong colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy
AT xiaoxia colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy
AT lujianwei colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy
AT qianxiaoping colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy
AT liubaorui colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy
AT fengjifeng colorectalcancerpatientswithlowabundanceofkrasmutationmaybenefitfromegfrantibodytherapy